ALDH2 and endothelial dysfunction: Prior systemic ALDH2 gene transfer studies demonstrated cardioprotection against ischemia/reperfusion injury by lowering 4HNE levels [54], but the current CVEC-focused strategy addresses the emerging paradigm that endothelial dysfunction and capillary rarefaction are central to HFpEF pathology.